Renovis raises $45 million in funding

FRAMINGHAM (09/24/2003) - Bio/pharma company Renovis Inc. has raised US$45 million in funding to help it undertake preclinical and clinical trials of its drug candidates. The company focuses on the discovery and development of drugs to treat neurological diseases and disorders. Renovis has a Phase II candidate called REN-1654, which is for neuropathic pain. And later this year, the company will begin enrolling patients for a Phase I study for another drug candidate called REN-213, which is for patients with post-operative pain. The company also has a Phase III drug candidate for acute ischemic stroke called Cerovive, which is licensed to AstraZeneca PLC.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about AstraZeneca

Show Comments